

# IND Approval of Novel Immunotherapy for NHL: Intratumoral Administration of Novel Adjuvant ProLNG-001 and/or Personalized Cancer Vaccine ProV-001



ONCOLOGY	Preclinical
Product Type	Other-Bio.
Indication	Non-Hodgkin Lymphoma (NHL)
Target	B-cell receptor (BCR) variable region (idiotype)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> <li>• Activation of antigen presenting machineries, thereby increase the presentation of idio-type-derived neoantigen</li> <li>• Tumor-specific cellular immune response</li> </ul>
Competitiveness	<ul style="list-style-type: none"> <li>• Tumor specific immune response: Inducing highly tumor-specific immune response, minimizing off-target toxicities and adverse events</li> <li>• Long lasting efficacy: Inducing long-term memory response to prevent relapse, which is a significant unmet need in NHL</li> </ul>
Development Stage	Preclinical
Route of Administration	<ul style="list-style-type: none"> <li>- Intratumoral (i.t.) administration of ProLNG-001,</li> <li>- Subcutaneous (s.c.) administration of ProV-001</li> <li>(Arm A: ProLNG-001 (i.t.), Arm B: ProV-001 (s.c.), Arm C: ProLNG-001 (i.t.) + ProV-001 (s.c.))</li> </ul>

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*